Research programme: anti-inflammatory therapeutics - Noxopharm/Hudson Institute of Medical Research
Latest Information Update: 27 Mar 2023
At a glance
- Originator The Hudson Institute of Medical Research
- Developer Noxopharm; The Hudson Institute of Medical Research
- Class Anti-inflammatories
- Mechanism of Action MPYS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation